Investment archive

Investment feed — page 16

Back to latest investments

WhiteMatter (formerly QuilrAI) raises $20M Series A for enterprise AI-agent security

WhiteMatter (formerly QuilrAI) raises $20M Series A for enterprise AI-agent security

WhiteMatter, formerly called QuilrAI, issued a November 10, 2026 announcement for its $20M Series A led by Blumberg Capital with existing Crew Capital and Sprout & Oak. The company claims 2.25M Guardian control agents and 116B governed interactions; these are vendor assertions, not paying-customer counts or audited efficacy. Per-agent subscription terms and valuation undisclosed. This rebranding is not a separate fundraising event.

Primordial Labs announces $18M Series A led by Ballistic Ventures

Primordial Labs announces $18M Series A led by Ballistic Ventures

Company-issued Nov 10, 2026 announcement states an $18M Series A led by Ballistic Ventures, with existing investors Squadra Ventures and Lockheed Martin Ventures. Funds support Anura, a natural-language edge command interface, and existing military programme deployments. The Oct 7 General Dynamics teaming agreement is for further integration, not proof of a completed Abrams rollout. Valuation, legal closing day and historical seed amount undisclosed. Do not add an Oct 2026 Form D to this round as new proceeds.

Stage 2 Capital closes $100M combined across Venture Fund IV and Catalyst IV

Stage 2 Capital closes $100M combined across Venture Fund IV and Catalyst IV

Stage 2 Capital's November 10, 2026 manager-issued release confirms $100M CLOSED IN TOTAL across two distinct vehicles: Venture Fund IV (Seed–Series A, $2M–$5M checks) and Catalyst IV (pre-seed, $200K checks). Individual vehicle sizes, LP splits and precise legal close dates are undisclosed. Do not record $100M for each fund or compare it as a like-for-like single vehicle with 2022's separate $150M Fund III.

Zus Health raises $33M Series B led by Drive Capital for connected clinical data and AI workflows

Zus Health raises $33M Series B led by Drive Capital for connected clinical data and AI workflows

Zus Health announced $33 million Series B on November 10, 2026, led by Drive Capital with new Sanofi Ventures, HealthX Ventures and Alumni Ventures, alongside existing investors. Company reports more than $100M cumulative investment. Its Zus Aggregated Profile (ZAP), national network and AI Generated Patient Summaries support clinical workflows; 110M August network transactions and 39M YTD evidence citations are platform usage, not paying customers or revenue. Zus has QHIN candidacy, not confirmed QHIN designation. Exact legal closing date and valuation undisclosed.

Oyster Therapeutics (formerly Kesmalea) announces $60M Series A-2 led by 4BIO Capital

Oyster Therapeutics (formerly Kesmalea) announces $60M Series A-2 led by 4BIO Capital

On November 10, 2026, Oyster Therapeutics (formerly Kesmalea) announced a $60M Series A-2 led by 4BIO Capital. A separate 4BIO investor release uses the shorter label Series A; both describe the same transaction. Financing supports preclinical SELFTAC targeted protein degradation and an oral tau-targeting Alzheimer’s drug candidate, not a demonstrated clinical medicine. Previously disclosed 2022/2023 financing is separate historical funding and not added again. Valuation and exact legal close date undisclosed.

redalpine capital VIII reaches $250M final close for European frontier technology

redalpine capital VIII reaches $250M final close for European frontier technology

Redalpine announced the oversubscribed $250M final close of RAC VIII on November 10, 2026; actual contractual close day was not separately disclosed. The fund plans around 20 European Seed and Series A investments with $1M–$15M initial cheques. Named institutional LPs include Aviva Investors, Flexstone Partners and KfW. This is fund LP capital, not funding raised by a startup nor redalpine's $1.4B+ firm-wide AUM.

Alta (formerly Metal) raises $47.5M Series A led by Index Ventures; total disclosed funding $80M

Alta (formerly Metal) raises $47.5M Series A led by Index Ventures; total disclosed funding $80M

On Nov 10 Alta announced a $47.5M Index Ventures-led Series A with GV, Blackbird Ventures, Square Peg and Capital49 participating. Its previously reported $32.5M seed brings cumulative disclosed funding to $80M. Airwallex is a design/launch partner and prior investor. Valuation undisclosed; $80M is not new round proceeds.

Stripe confirms OpenRouter acquisition completed

Stripe confirms OpenRouter acquisition completed

Stripe confirmed at 19:42 UTC on November 10, 2026 that OpenRouter is now part of Stripe, and OpenRouter confirmed the completion minutes later. Agreement announced Aug. 19, 2026. Transaction consideration is not officially disclosed; NYT/TechCrunch reported ~$7.5B. OpenRouter will continue to operate its multi-model inference gateway and says it remains model-neutral.

Mavria discloses $130M cumulative pre-seed and seed financing; Paradigm leads latest

Mavria discloses $130M cumulative pre-seed and seed financing; Paradigm leads latest

Company and legal counsel confirm $130M raised to date across pre-seed and seed rounds. This is NOT one incremental $130M round, individual tranches unspecified. Latest round carries stated $1B valuation (basis unknown). October SEC Form D $75M sales is not added separately.

argenx agrees to acquire Unnatural Products: $550M upfront, up to $595M conditional milestones

argenx agrees to acquire Unnatural Products: $550M upfront, up to $595M conditional milestones

On Nov 9 2026 argenx signed a definitive agreement to acquire remaining shares of Unnatural Products, where it already holds a minority stake. $550M cash payable at closing plus up to $595M development/regulatory contingent payments, up to $1.145B total potential consideration (approximately $1.15B). Boards approved but close expected before end 2026 subject to conditions, NOT completed as of Nov 14. Do not present this as venture capital raised or $1.15B guaranteed cash.

Delix Therapeutics closes $100M Series C for depression drug trials

Delix Therapeutics closes $100M Series C for depression drug trials

Neuroscience drug developer funds planned Phase IIb testing of zalsupindole and other neuroplastogen programs.

Nominal announces $240M Series C at $3B valuation led by Lightspeed and Insight

Nominal announces $240M Series C at $3B valuation led by Lightspeed and Insight

Nominal announced a $240M Series C on November 9, 2026, led by Lightspeed and co-led by Insight Partners at a company-stated $3B valuation. The round is distinct from its $75M June 2025 Series B and $80M March 2026 extension; U.S. Air Force STRATFI funding is not equity. Nominal Analyst remains in preview and revenue is undisclosed.